The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status

SIMPLE SUMMARY: When evaluating new cancer therapies in clinical trials, it may take a long time to estimate their effectiveness on overall survival, an outcome typically of main interest to regulatory decision-makers. To expedite access to new therapies for patients, regulatory agencies often make...

Descripción completa

Detalles Bibliográficos
Autores principales: Poad, Heather, Khan, Sam, Wheaton, Lorna, Thomas, Anne, Sweeting, Michael, Bujkiewicz, Sylwia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654686/
https://www.ncbi.nlm.nih.gov/pubmed/36358810
http://dx.doi.org/10.3390/cancers14215391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654686/
https://www.ncbi.nlm.nih.gov/pubmed/36358810
http://dx.doi.org/10.3390/cancers14215391

Ejemplares similares